Overview

Anti-PD1-antibody and Pulsed HHI for Advanced BCC

Status:
Recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the tumour response, safety and induction of immune response in patients with advanced BCC treated with a combination of anti-PD1 antibody and pulsed hedgehog inhibitor.

Phase:

Phase 2

Details

Lead Sponsor:

Reinhard Dummer

Collaborators:

Sanofi
Sun Pharmaceutical Industries Ltd

Treatments:

Cemiplimab